Phase II trial of SAV001-H, an inactivated HIV vaccine, in patients with HIV-1 infections.
Latest Information Update: 10 Nov 2024
Price :
$35 *
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 29 Oct 2024 According to a Naobios media release, Naobios, a CDMO (Contract Development and Manufacturing Organization) and Sumagen Canada Inc (Sumagen), have announced the production of the HIV-1 vaccine candidate at bench scale. Naobios and Sumagen will now focus on industrial scale-up activities up until mid-2025, followed by cGMP production to bring Sumagen's HIV-1 vaccine candidate into phase I/II clinical trials, by the end of 2025.
- 12 Sep 2013 New trial record